Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Assmann

Showing results (241-250 of 495) with videos related to

Pageof 50
Sort By:
Versicherungsmedizin|July 4, 2008
[Risk factor calculator for medical underwriting of life insurers based on the PROCAM study]A Geritse, G Müller, T Trompetter, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 14, 1999
Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart diseaseG Assmann, P Cullen, F Jossa, et al.
European Journal of Biochemistry|July 1, 1981
Displacement of the human apoprotein A-I by the human apoprotein A-II from complexes of (apoprotein A-I)-phosphatidylcholine-cholesterolM Rosseneu, P Van Tornout, M J Lievens, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1983
Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-i) with high density lipoproteinsG Schmitz, G Assmann, S C Rall, et al.
The Journal of Biological Chemistry|January 23, 1999
Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2-/ sterol carrier protein x-deficient miceP Ellinghaus, C Wolfrum, G Assmann, et al.
Revista Espanola De Cardiologia|January 1, 1987
[Strategy for the prevention of ischemic heart disease. Directives from the European Society of Atherosclerosis]G Assmann, B Lewis, M Mancini, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 6, 2001
Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancerF Eckel, C Lersch, F Lippl, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 20, 2000
Use of longer extension phases to improve yield of high molecular weight products in differential display PCRS Lorkowski, P Ellinghaus, E A Galinski, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 1, 1995
HDL3 stimulates multiple signaling pathways in human skin fibroblastsM Walter, H Reinecke, J R Nofer, et al.
Clinical & Experimental Metastasis|September 1, 1996
Detection of the metastatic potential of blood-borne and immunomagnetically enriched epithelial cells by quantitative erbB-2 RT-PCRB Brandt, C Griwatz, S Heidl, et al.
Pageof 50

Showing results (241-250 of 495) with videos related to

Sort By:
Pageof 50
Versicherungsmedizin|July 4, 2008
[Risk factor calculator for medical underwriting of life insurers based on the PROCAM study]A Geritse, G Müller, T Trompetter, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 14, 1999
Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart diseaseG Assmann, P Cullen, F Jossa, et al.
European Journal of Biochemistry|July 1, 1981
Displacement of the human apoprotein A-I by the human apoprotein A-II from complexes of (apoprotein A-I)-phosphatidylcholine-cholesterolM Rosseneu, P Van Tornout, M J Lievens, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1983
Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-i) with high density lipoproteinsG Schmitz, G Assmann, S C Rall, et al.
The Journal of Biological Chemistry|January 23, 1999
Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2-/ sterol carrier protein x-deficient miceP Ellinghaus, C Wolfrum, G Assmann, et al.
Revista Espanola De Cardiologia|January 1, 1987
[Strategy for the prevention of ischemic heart disease. Directives from the European Society of Atherosclerosis]G Assmann, B Lewis, M Mancini, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 6, 2001
Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancerF Eckel, C Lersch, F Lippl, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 20, 2000
Use of longer extension phases to improve yield of high molecular weight products in differential display PCRS Lorkowski, P Ellinghaus, E A Galinski, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 1, 1995
HDL3 stimulates multiple signaling pathways in human skin fibroblastsM Walter, H Reinecke, J R Nofer, et al.
Clinical & Experimental Metastasis|September 1, 1996
Detection of the metastatic potential of blood-borne and immunomagnetically enriched epithelial cells by quantitative erbB-2 RT-PCRB Brandt, C Griwatz, S Heidl, et al.
Pageof 50